Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma
Status:
Not yet recruiting
Trial end date:
2023-11-15
Target enrollment:
Participant gender:
Summary
Kligman's trio remains the gold standard treatment for melasma. It contain hydroquinone which
is an effective anti-melanogenic compound but that has poor tolerance and numerous
side-effects. Thiamidol has been proven to be at least as effective as hydroquinone and has a
very good safety profile. The objective of this study is to compare the Kligman's trio to the
same preparation in which hydroquinone is replaced by thiamidol.